EPA:AELIS - Euronext Paris - Matif - FR0014007ZB4 - Common Stock - Currency: EUR
EPA:AELIS (3/7/2025, 7:00:00 PM)
1.41
-0.04 (-2.76%)
The current stock price of AELIS.PA is 1.41 EUR. In the past month the price decreased by -36.49%. In the past year, price decreased by -89.52%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Aelis Farma SA engages in the research and development of pharmaceutical products. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 26 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
AELIS FARMA SAS
Neurocentre Francois Magendie 146 Rue Leo, Saignat
Bordeaux NOUVELLE-AQUITAINE FR
Employees: 26
Company Website: https://www.aelisfarma.com/
Investor Relations: http://www.aelisfarma.com/investors
Phone: 33557573770
The current stock price of AELIS.PA is 1.41 EUR. The price decreased by -2.76% in the last trading session.
The exchange symbol of AELIS FARMA SAS is AELIS and it is listed on the Euronext Paris - Matif exchange.
AELIS.PA stock is listed on the Euronext Paris - Matif exchange.
10 analysts have analysed AELIS.PA and the average price target is 9.28 EUR. This implies a price increase of 558.3% is expected in the next year compared to the current price of 1.41. Check the AELIS FARMA SAS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AELIS FARMA SAS (AELIS.PA) has a market capitalization of 19.33M EUR. This makes AELIS.PA a Nano Cap stock.
AELIS FARMA SAS (AELIS.PA) currently has 26 employees.
AELIS FARMA SAS (AELIS.PA) has a resistance level at 1.77. Check the full technical report for a detailed analysis of AELIS.PA support and resistance levels.
The Revenue of AELIS FARMA SAS (AELIS.PA) is expected to decline by -63.24% in the next year. Check the estimates tab for more information on the AELIS.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AELIS.PA does not pay a dividend.
AELIS FARMA SAS (AELIS.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.53).
ChartMill assigns a fundamental rating of 2 / 10 to AELIS.PA. The financial health of AELIS.PA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months AELIS.PA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS decreased by -29.01% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -17.92% | ||
ROE | -35.5% | ||
Debt/Equity | 0.07 |
ChartMill assigns a Buy % Consensus number of 82% to AELIS.PA. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -30.17% and a revenue growth -63.24% for AELIS.PA